2024
Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealth
2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, Knight G, Meghji J, Nguyen L, Rachow A, Schumacher S, Mirzayev F, Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nature Communications 2023, 14: 6182. PMID: 37794037, PMCID: PMC10550952, DOI: 10.1038/s41467-023-41937-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsRifampicin-resistant tuberculosisRR-TBGlobal burdenSubstantial short-term morbidityRifampicin-susceptible tuberculosisShort-term morbidityOverall disease burdenLong-term health impactsPost-treatment careTB survivorsDisease burdenTreatment outcomesTuberculosis survivorsCase detectionLife yearsRifampicin resistanceTuberculosisHealth impactsBurdenHealth expenditureDiseaseSurvivorsMathematical modeling analysisFormer Soviet Union countries
2022
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania
Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, Minde J, Chisonjela F, Cohen T, Menzies NA. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. The Lancet Global Health 2022, 10: e1646-e1654. PMID: 36240830, PMCID: PMC9553191, DOI: 10.1016/s2214-109x(22)00372-2.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyCD4 cell countAntiretroviral therapyCell countART cohortAverage CD4 cell countHigher CD4 cell countsLarge HIV treatment programHealth impactsTuberculosis preventive treatmentHIV treatment programsLifetime costsIncremental lifetime costLifetime health benefitsCourse of infectionGreater health gainsLong-term healthART initiationTreat guidelinesHIV cohortPreventive therapyTuberculosis riskUS National InstitutesHIV programsSubgroup analysis
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF test